Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia

NCT05438485 | Terminated

• 1 other identifier: HST21-NH03
• Study Type: observational
• Target: 11
• Locations: 3 countries
• Sites: 3

Brief Summary

The JUMP (Journey to Understand MMA and PA) Study is being conducted by HemoShear Therapeutics and AllStripes, a rare disease online research platform. JUMP is designed to accelerate understanding of the natural course of methylmalonic acidemia (MMA) and propionic acidemia (PA) disease and treatment for families, researchers, clinicians and industry. The study will collect and provide patient medical record information from multiple institutions for families to access in one place at no cost. AllStripes will remove identifying information like name and address from these medical records and aggregate this data for the HemoShear team to better understand the medical experience and progression of MMA and PA over time. In addition, academic researchers, healthcare practitioners and patient advocacy groups can apply to use the collective patient community data to answer specific research questions at no cost. HemoShear is collecting natural history data on MMA and PA because the company needs insight into the real-world experience of many patients to better understand the disease and be able to scientifically demonstrate whether the potential new treatment they are developing is effective in improving outcomes. This natural history study will include retrospective and prospective components. The retrospective component will consist of data abstracted from primarily electronic health records (eHR) and some paper records. The prospective component will include ongoing collection of medical records from enrolled participants, and participants may opt in to complete health-related questionnaires and an optional genetic testing sub-study. After signing informed consent, participants or their legal guardians will grant permission to AllStripes to collect their health records for data abstraction. Participants may opt into an optional no cost genetic testing sub-study. The JUMP (Journey to Understand MMA and PA) sub-study will help assess whether the genetic variant of the affected person may relate to disease severity and treatment response. Getting genetic testing will enable participants to understand the genetic mutation that causes their type of methylmalonic acidemia (MMA) or propionic acidemia (PA). Knowing the genetic mutations (whether from the MMUT, MMAA or MMAB gene or PCCA or PCCB) can help the impacted person, their caregivers and healthcare professionals understand the potential course of disease and select approaches to better manage the disease. The additional information will enable HemoShear and AllStripes to understand whether different genetic variants impact the disease journey and outcomes. A separate informed consent will be obtained for participating in the sub-study.

Conditions

Methylmalonic Acidemia; Propionic Acidemia

Keywords

Methylmalonic Acidemia; Propionic Acidemia; Organic Acidemia; Inborn errors of metabolism; PCCA; PCCB; Propionyl-coenzyme A carboxylase; MMUT; Methylmalonyl-CoA mutase; Metabolic disease; Genetic disease; HemoShear; Natural History Study; JUMP

Outcome Measures

Primary Outcomes (1)

• Understanding of the natural course of methylmalonic acidemia (MMA) and propionic acidemia (PA) disease and treatment for families, researchers, clinicians and industry.

  5 years

Study Arms (2)

Methylmalonic Acidemia (MMA)

Approximately 60 subjects with Methylmalonic Acidemia

Other: Registry

Propionic Acidemia (PA)

Approximately 60 subjects with Propionic Acidemia

Other: Registry

Interventions

Registry OTHER

Observational (Registry)

Methylmalonic Acidemia (MMA); Propionic Acidemia (PA)

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Approximately 120 participants will be enrolled from the United States, Canada, and the United Kingdom.

You may qualify if:

• Participant or participant's legal guardian must provide signed, informed eConsent/eAssent prior to releasing health records or performing any study-related procedures.
• Confirmed diagnosis of MMA or PA.
• Reside in the US, Canada, or United Kingdom and have all medical records available for abstraction.

You may not qualify if:

• \. Participant or participant's legal guardian is unable to provide complete access to medical records.

Sponsors & Collaborators

• HemoShear Therapeutics: lead
• AllStripes Research Inc.: collaborator
• Prometrika, LLC: collaborator
• Genome Medical: collaborator

Study Sites (3)

AllStripes

San Francisco, California, 94551, United States

Location

AllStripes

Remote, Remote, Canada

Location

AllStripes

Remote, Remote, United Kingdom

Location

Related Links

• Link to information about participation in JUMP
• Link to information about optional genetic testing. Only participants in JUMP will receive link to optional genetic testing.
• Link to information about participation in JUMP for MMA
• Link to information about participation in JUMP for PA

MeSH Terms

Conditions

Methylmalonic acidemia; Propionic Acidemia; Metabolism, Inborn Errors; Metabolic Diseases; Genetic Diseases, Inborn

Interventions

Registries

Condition Hierarchy (Ancestors)

Amino Acid Metabolism, Inborn Errors; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Records; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 12 Months
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2022
• First Posted: June 30, 2022
• Study Start: August 27, 2021
• Primary Completion: October 20, 2023
• Study Completion: October 20, 2023
• Last Updated: December 27, 2023

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1); CA (1); GB (1)